2022 World Conference on Lung Cancer (ePosters)-EP16.02-005. Liquid Biopsy Detects Genomic Drivers in Non-small Cell Lung Cancer without EGFR Mutations by Single-plex Testing: WJOG13620L

EP16.02-005. Liquid Biopsy Detects Genomic Drivers in Non-small Cell Lung Cancer without EGFR Mutations by Single-plex Testing: WJOG13620L

Back to course

Pdf Summary

A study was conducted to determine if a plasma-based next-generation sequencing assay could detect clinically relevant genomic alterations in advanced non-small cell lung cancer (NSCLC) patients without EGFR mutations. The study enrolled 72 patients with stage IIIB-IV or relapsed, untreated non-Sq NSCLC. Tumor tissue was tested for EGFR mutations using single-plex gene analysis and found to be negative for any driver mutation.<br /><br />Liquid biopsy using Guardant360 was performed to analyze plasma samples. The primary outcome was the percentage of samples with a pathogenic alteration in genes including EGFR, ALK, ROS1, BRAF, MET, RET, ERBB2, KRAS, or NTRK1. Relevant genomic alterations were detected in 29.2% of patients, including KRAS mutations, EGFR mutations, ERBB2 mutations, BRAF V600E, and RET fusion.<br /><br />The median time from sample submission to obtaining results was 8 days. Tumor tissue re-analysis confirmed the findings from the liquid biopsy for two patients with EGFR L858R and BRAF V600E mutations, who received targeted therapy based on the results. The study concluded that a follow-on plasma-based next-generation sequencing assay can detect previously unknown driver alterations in patients with advanced non-Sq NSCLC without EGFR mutations, providing results within a short timeframe.<br /><br />The findings suggest that comprehensive liquid biopsy may be considered prior to initiating first-line treatment for advanced non-Sq NSCLC patients when no mutations are detected by initial single-plex tissue testing. This approach may help identify actionable alterations that could be missed by standard evaluation methods. The study also revealed that nearly 70% of advanced non-Sq NSCLC patients in Japan have actionable genomic alterations. Overall, liquid biopsy appears to be a valuable tool for detecting genomic drivers in non-small cell lung cancer without EGFR mutations.

Asset Subtitle

Daisuke Hazama

Meta Tag

Speaker Daisuke Hazama

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

plasma-based next-generation sequencing assay

clinically relevant genomic alterations

non-small cell lung cancer

EGFR mutations

tumor tissue

Guardant360

liquid biopsy

pathogenic alteration

driver mutation

comprehensive liquid biopsy